

Unlocking the Secrets of Alzheimer's Disease and Related Dementias: Mastering Fluid Biomarkers

Friday, July 25, 2025 | 8 a.m. – 5 p.m.

Westin Harbour Castle- Harbour B — Toronto, Canada

All times are in Eastern Standard Time

In-person attendance only

Overview

The fluid biomarkers field for Alzheimer's disease (AD), and other dementias is rapidly expanding. This workshop aims to provide participants with an in-depth understanding of the fundamental principles, inherent limitations, and clinical and research applications of the most common AD biomarkers present in cerebrospinal fluid (CSF) and blood. This workshop will include fundamental laboratory-focused sessions that capture the basics of neurochemistry, sample pre-analytics, assay methods and development, quality control, and regulatory considerations. It will also incorporate clinical practice-focused sessions that cover considerations for AD fluid biomarker implementation, the context of use, disclosure, and the gaps and opportunities in this field.

Organizing Committee

- Jeffrey L. Dage, Indiana University School of Medicine, United States
- Marta del Campo, Barcelonaβeta Brain Research Center, Spain
- Charlotte Teunissen, VU University Medical Center, Netherlands
- Ashvini Keshavan, University College London, United Kingdom
- Alicia Algeciras-Schimnich, Mayo Clinic, United States

Target Audience

This ISTAART immersive workshop is designed for individuals at the Beginner, Intermediate, and Advanced levels in Clinical Practice, Research, Teaching, Industry: biotech and diagnostic.

Learning Objectives

- 1. Demonstrate an in-depth understanding of the fundamental principles, inherent limitations, and clinical and research applications of the most common biomarkers used in AD and found in CSF and blood.
- 2. Discuss the status of the field of biofluid based biomarkers for other cause of dementia

(non-AD dementia)

3. Understand the fundamentals of CSF physiology, the basics of neurochemistry, technical issues of sample collection, storage, analysis methods, quality control, and regulatory issues.

Registration

Educational workshops are offered for in-person attendance only. Workshops require a separate registration fee in addition to AAIC full conference registration, or they may be purchased as stand-alone events. Visit <u>alz.org/AAIC</u>.

Agenda: July 25, 2025 | 8:00 am - 5:00 PM

Workshop Moderator: Ashvini Keshavan

Session 1: Laboratory - Basics			
Time	Session Details	Speakers and Moderator	
8:15-8:20 AM	Welcome Remarks	Ashvini Keshavan	
8:20-8:40 AM	Overview of Core CSF Alzheimer's Disease Biomarkers	Kaj Blennow	
8:45-9:05 AM	Overview of Core Blood Based Alzheimer's Disease Biomarkers	Henrik Zetterberg	
9:10-9:30 AM	5 Things to know: CSF and Blood Biomarkers and Analytics Overview	Inge Verberk	
9:35-9:45 AM	Q&A		
9:50-10:10 AM	Break		
Session 2: Biomarker Discovery			
10:15-10:35 AM	Accelerating Biomarker Discovery Through the Use of Large Panels	Yanaika Hok-A Hin	
10:40-11:00 AM	Non-AD Biomarkers (FTD, LBD, DS/AD, TBI, VCID)	Olivia Belbin	
11:05-11:25 AM	Emerging Fluid Biomarkers Specific to Alzheimer's Disease	Thomas Karikari	
11:30 AM-12:00 PM	Discussion and Poll Question		
12:05-1:05 PM	Lunch		
Session 3: Translational Considerations of CSF and Plasma Biomarkers			



Practical Considerations for Clinical mplementation of CSF and Blood Based biomarkers	Alicia Algeciras-Schimnich
Using Biofluid Markers for Clinical Trial Enrichment and Pharmacodynamics	Jeff Dage
Effects of Sociodemographics and Multiple Chronic Conditions on Biomarkers	Michelle Mielke
Q&A	
Break	
I - Case Based Approaches	
Appropriate Use Recommendations and Context of Use for CSF Biomarkers for	Jonathan Schott
Alzheimer's Disease and Other Dementia Case-Based Approach)	
Alzheimer's Disease and Other Dementia	Suzanne Schindler
Alzheimer's Disease and Other Dementia Case-Based Approach) Appropriate Use Recommendations and Context of Use for Blood Biomarkers for	Suzanne Schindler
	sing Biofluid Markers for Clinical Trial nrichment and Pharmacodynamics fects of Sociodemographics and Multiple nronic Conditions on Biomarkers &A reak - Case Based Approaches propriate Use Recommendations and